Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer GlobeNewswire - Thu Nov 14, 6:00AM CST

NVCT : 5.73 (-46.30%)
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Tue Nov 5, 6:00AM CST

NVCT : 5.73 (-46.30%)
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics GlobeNewswire - Wed Oct 23, 7:00AM CDT

NVCT : 5.73 (-46.30%)
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference GlobeNewswire - Mon Oct 7, 7:00AM CDT

NVCT : 5.73 (-46.30%)
People and teaching - Two Colleagues Talking About Markets
Bump up Your Long Term Portfolio Performance With Low Beta Stocks Barchart - Wed May 17, 2023

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 426.89 (+0.40%)
NERV : 2.32 (+0.43%)
STIX : 0.3000 (-19.14%)
SERA : 6.44 (-7.60%)
TCRX : 4.82 (-8.19%)
NVCT : 5.73 (-46.30%)
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights Globe Newswire - Fri Aug 5, 2022

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S....

NVCT : 5.73 (-46.30%)
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement Globe Newswire - Mon Aug 1, 2022

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused...

NVCT : 5.73 (-46.30%)
5 Best Performing Micro-Cap Stocks Through the First Half of 2022 Spotlight Growth - Tue Jul 5, 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

^BTCUSD : 89,293.58 (+1.22%)
^BTCUSDT : 89,386.07 (+1.34%)
FEDU : 10.96 (-2.14%)
NERV : 2.32 (+0.43%)
TRVI : 2.86 (unch)
NVCT : 5.73 (-46.30%)
HUSA : 1.5300 (+3.38%)
Nuvectis Pharma Announces FDA Clearance of IND for NXP800 Globe Newswire - Tue Jun 21, 2022

FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of...

NVCT : 5.73 (-46.30%)
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients Globe Newswire - Mon Jun 13, 2022

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development...

NVCT : 5.73 (-46.30%)

Barchart Exclusives

Stock Index Futures Plunge as Fed Rate Cut Bets Wane, U.S. Retail Sales Data in Focus Barchart - 31 minutes ago
December S&P 500 E-Mini futures (ESZ24) are down -0.58%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.90% this morning after Federal Reserve Chair Jerome Powell indicated the central bank was in no rush to lower interest rates, while investors geared up for a flurry of U.S. economic data, with a particular focus on the retail sales report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot